ANKARA, Feb 11 (Bernama-Anadolu) -- The United States drug regulator has declined to review Moderna’s application for an mRNA influenza vaccine, saying the company’s main late-stage study did not use the most appropriate comparison shot, the company said Tuesday, Anadolu Ajansi (AA) reported.